CTOs on the Move

Kinerase

www.kinerase.com

 
Kinerase is a Aliso Viejo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kinerase.com
  • 1 Enterprise Kinerase Support
    Aliso Viejo, CA USA 92656
  • Phone: 800.321.4576

Executives

Name Title Contact Details

Similar Companies

Diagnocure

DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.

People

People, Pets and Vets is a doctor-led organization that partners with veterinarians to help them reach their full potential.

EMR Experts

EMR Experts, Inc is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prince William Health System

Prince William Health System is a Manassas, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Naveos

NAVEOS® is the proven leader in maximizing the value of governmental program reimbursements for healthcare providers. Since 2005, our superior approach to data analytics has enabled healthcare providers to realize almost one billion dollars in additional DSH/340B reimbursement payments. NAVEOS® has developed a fully integrated DSH/340B software solution with a national eligibility verification network for both Medicare and Medicaid data. This system, which is the most robust in the industry, uses sophisticated algorithms to match eligibility data with patient data, applies the most up to date Federal and State regulatory parameters, then builds comprehensive deliverables for supporting DSH/340B filings. By leveraging our state-of-the-art technology and unsurpassed domain expertise, we generate best-in-class deliverables that yield impressive value and achieve a stellar (99.7%) audit acceptance rate.